
THE ARISING

OCTOBER 30, 2026 · JOHN GRIFFIN, MD

When technology earns its place



Original conceptual illustration · Keeping the clinician in the loop

Technology earns its place by helping people do something that matters. This edition considers clinical AI, glucose monitoring, kidney care, sleep and rehabilitation, alongside emerging brain biology. A faster process or a promising mechanism is a beginning; patient-important benefit is a separate question.

Ten full written articles · Alive. Awake. Aware.

In this edition

01 A clinical AI teammate finds toxicities—but it earns its place by helping people do the work

02 The glucose sensor crossed a boundary: benefit without insulin therapy

03 In a critically ill kidney, the choice of dialysis may matter far more than the machine

04 Dialysis may be near—but the capacity to walk is still worth fighting for

05 A better night for people caught between insomnia and sleep apnea

06 What an AI discharge plan can accomplish when a clinician remains in the room

07 A familiar antiseptic fails an unusually useful intensive-care test

08 Dopamine is essential for movement. Giving more has not restored movement after stroke.

09 The aging brain may be responding to a damaged building block of life

10 The cells guarding the brain’s blood vessels have their own conversation

About this copy

Recovered and prepared October 31, 2026, from the dated source issue or existing reader selection. The issue date is preserved; this PDF does not establish a publication date. Source qualifications are retained. This packaging pass is not a fresh independent audit of every study.

Use NEWSLETTER.html for copying into Substack and upload the image files separately. The longer original written-article reference, where supplied, is separate from this reader selection.

01 / A clinical AI teammate finds toxicities—but it earns its place by helping people do the work

October 29, 2026 · Prospective silent deployment + randomized staff crossover; retrospective validation · Primary source

Cancer immunotherapy can work remarkably well, but immune-related adverse events may emerge in clinical notes before they appear in a clean research database. An October 29 Nature Cancer study tested a narrower, more useful ambition for an AI agent: identify, characterize, and help people verify possible treatment toxicities. It is an example of AI designed around a real clinical research task rather than a promise to replace a clinician.

On retrospective records, the system achieved a macro-F1 of 0.92 for detecting current events, but only 0.66 for classifying multiple severity grades. During three months of silent prospective deployment, binary F1 dropped to 0.72–0.79. In a randomized crossover evaluation of trial staff, assistance cut annotation time by 2.71 minutes per note, increased the odds of an exact complete match (OR 1.45, 95% CI 1.01–2.08), and improved inter-rater agreement. The authors estimated about $0.02 per note for the best configuration, a model-use cost rather than the full implementation cost.

The distinction between retrospectively optimized accuracy and performance on incoming notes matters. The trial measured annotation quality and speed—not whether an oncologist made fewer harmful treatment decisions or whether patients lived longer. Yet these are measurable, realistic gains.

Clinical reading: Worth a supervised research-workflow pilot; not autonomous toxicity triage or independent patient management.

Source edition: October 30, 2026 · AR-20261030-READER-01 · existing reader feature

02 / The glucose sensor crossed a boundary: benefit without insulin therapy

October 14, 2026 online; October 29 journal issue · Randomized multicenter effectiveness trial; older online result revisited · Primary source

Continuous glucose monitoring began as a tool for people who depended on insulin. A major U.S. primary-care trial published online October 14 suggests a wider role: an unobtrusive source of feedback for adults with type 2 diabetes who were not using insulin. This is older than our 24-hour news window, and it has been brought forward for its clinical importance, not mislabeled as an overnight discovery.

At 22 primary-care practices, 145 adults were assigned to continuous monitoring and 138 to routine care over 26 weeks. HbA1c fell from 8.8% to 7.2% with CGM and from 8.7% to 8.0% in controls: an adjusted between-group difference of −0.9 percentage points (95% CI −1.1 to −0.6). CGM users also spent 21 percentage points more time in the 70–180 mg/dL range (95% CI 16–26). No severe hypoglycemia occurred. The study was funded by Dexcom.

The practical question is what enabled the improvement: feedback, behavior changes, clinician attention, treatment adjustments, or some combination. We cannot attribute the effect to a specific mechanism without additional analysis. Nor does a better six-month glucose profile alone establish reduced cardiovascular events. But this RCT shows a potentially meaningful short-term disease-control benefit in an everyday primary-care setting.

Clinical reading: A practice-relevant trial for discussing CGM with appropriate non–insulin-treated adults; coverage and individualized management require current review.

Source edition: October 30, 2026 · AR-20261030-READER-02 · existing reader feature

03 / In a critically ill kidney, the choice of dialysis may matter far more than the machine

October 14, 2026 online; October 29 journal issue · Multicenter randomized noninferiority trial, stopped early; older online result revisited · Primary source

In critical care, intermittent dialysis and continuous renal-replacement therapy are not interchangeable conveniences. A multicenter trial published October 14 tested whether starting with intermittent hemodialysis was noninferior to continuous therapy for patients with severe acute kidney injury. It is included as a dated clinical anchor, not a newly published October 30 result.

Of 554 randomized patients, 535 were included in the intention-to-treat analysis. Major adverse kidney events at day 90—death, dialysis dependence, or a large creatinine increase—occurred in 78.1% of the intermittent group and 71.6% of the continuous group (adjusted absolute difference 6.28 percentage points, 95% CI −1.22 to 13.79). The prespecified noninferiority criterion was not satisfied. Ninety-day mortality was 63.1% versus 53.5%; the reported hazard ratio for death was 1.30 (95% CI 1.04–1.63). Enrollment stopped early after interim mortality signals.

Early termination, an open-label protocol and the very ill population complicate how broadly the difference should be applied. The composite primary outcome did not show a statistically certain superiority difference, while mortality raised an important safety signal. This is a study for nephrologists and intensivists to examine closely, including treatment timing, hemodynamic tolerance, selection criteria and institutional expertise. The interesting question for The Arising is not technology for its own sake: it is whether the way a therapy is delivered changes survival, recovery and independence.

Clinical reading: Immediate specialty appraisal warranted; do not reduce an ICU modality choice to a general outpatient recommendation.

Source edition: October 30, 2026 · AR-20261030-READER-03 · existing reader feature

04 / Dialysis may be near—but the capacity to walk is still worth fighting for

October 30, 2026 PubMed publication record · Small parallel-group randomized clinical trial · Primary source

For someone with stage 4 or 5 kidney disease, the ability to walk farther can mean more than an improved laboratory value. A new randomized trial tested a 12-week home-based exercise program delivered with telehealth support to adults who had not yet started dialysis. It is a small study with an unusually tangible endpoint.

Fifty-four patients were randomized and 51 completed analysis. The intervention group gained an average 29.41 meters on the six-minute walk test, while usual-care controls declined by 19.27 meters—roughly a 48.7-meter difference in change, with $P<0.001$. The participants also reported improvements in fatigue, mood, sleep and quality of life, with favorable changes on functional and sarcopenia-risk measures. Forty percent used the web platform; sixty percent received video-based support.

The program was short, the sample was small and the complete-case analysis can overstate certainty if attrition was related to outcome. We do not yet know whether gains last, prevent falls or affect hospitalizations. Nevertheless, walking distance is meaningful function, and the remote delivery model is transferable as a research question.

Clinical reading: Promising adjunct in selected patients with advanced CKD after exercise clearance and individualized safety assessment.

Source edition: October 30, 2026 · AR-20261030-READER-04 · existing reader feature

05 / A better night for people caught between insomnia and sleep apnea

October 29, 2026 PubMed publication record · Randomized, blinded-assessment trial; 88 participants · Primary source

Insomnia and obstructive sleep apnea commonly coexist, and treating one while ignoring the other can leave patients exhausted. An 88-person randomized study tested six weekly clinician-guided online CBT-I sessions against sleep-hygiene education in people with both conditions. The results are directly relevant to Sleep Observatory readers because they measured symptoms, sleep quality and apnea physiology separately.

At three months, Insomnia Severity Index scores improved 9.5 points with guided CBT-I versus 4.0 with education, a 5.5-point difference in change. Pittsburgh Sleep Quality Index scores improved 4.9 versus 1.8 points; subjective sleepiness fell 3.4 versus 1.0. Immediately after treatment, the apnea-hypopnea index changed by −6.0 versus +2.0 events per hour. Sleepiness briefly increased in weeks two to four, although no sleepiness-related functional adverse events were reported in the abstract.

This is more useful than a vague claim that sleep advice helps. It identifies a defined protocol, trained guidance, a specific comparator and measured outcomes. The modest size and short follow-up still matter, and the study does not show CBT-I replaces positive airway pressure or prevents dementia. We should update the living Sleep booklet with a patient pathway for concurrent insomnia and apnea, and reserve the more speculative brain-health connections for the evidence map.

Clinical reading: Supports specialist review of guided CBT-I as an adjunct for coexisting insomnia and apnea, with apnea care maintained.

Source edition: October 30, 2026 · AR-20261030-READER-05 · existing reader feature

06 / What an AI discharge plan can accomplish when a clinician remains in the room

October 29, 2026 PubMed publication record · Single-center randomized trial; 90 post-surgical patients · Primary source

After stomach or colorectal cancer surgery, nutritional guidance can become another burden for someone who is already recovering. A randomized trial tested a clinician-reviewed, AI-facilitated discharge plan that translated individual needs into quantified food and protein targets. The comparison was standard generic advice—not equally individualized counseling without AI.

Ninety people were randomized. At 30 days, 66.7% of the intervention group met at least 90% of their energy targets compared with 40.0% of controls (odds ratio 3.0, 95% CI 1.3–7.1). Protein adequacy was 62.2% versus 35.6% (OR 2.9, 95% CI 1.2–6.8). Clinician time per patient was 8.2 versus 12.5 minutes. Patient-reported fatigue, appetite and digestive symptoms also favored the intervention, while weight change, blood nutritional markers and complications did not differ significantly.

The exact contribution of the language model cannot be isolated: the intervention combined individualized attention, explicit quantitative goals, generated text and clinician review. That is not a weakness to ignore; it is the central implementation question.

Clinical reading: Interesting supervised discharge-support research, not evidence that unsupervised chatbot diet advice improves recovery.

Source edition: October 30, 2026 · AR-20261030-READER-06 · existing reader feature

07 / A familiar antiseptic fails an unusually useful intensive-care test

October 29, 2026 PubMed publication record · Pragmatic cluster-randomized crossover trial in six ICUs · Primary source

Some interventions become habits because they fit smoothly into care bundles. A pragmatic trial in six medical ICUs asked whether adding 0.12% chlorhexidine to otherwise standardized oral care prevented ventilator-associated pneumonia. The study focused on the incremental contribution of one common ingredient, not whether oral hygiene matters.

Across 1,035 patients and 10,024 ventilator-days, the pneumonia rate was 16.9 per 1,000 ventilator-days without chlorhexidine versus 18.8 with it. The adjusted incidence rate ratio was 1.08 (95% CI 0.84–1.38, P=0.56). Twenty-eight-day mortality was 28.7% without chlorhexidine and 26.4% with it, without a significant adjusted difference. The chlorhexidine periods were associated with ICU stays 0.89 days longer on average (95% CI 0.19–1.58).

The trial took place in one hospital system and used a defined clinical-pulmonary-infection score, so diagnostic standards and generalizability need consideration. It did not find a reduction in the main infectious outcome. That negative result is useful because it invites a practical question: which parts of our routines earn their burden and cost? This is a better patient-safety story than another general exhortation to improve adherence.

Clinical reading: Relevant to critical-care protocol appraisal; do not alter unit infection-control policy solely from one trial.

Source edition: October 30, 2026 · AR-20261030-READER-07 · existing reader feature

08 / Dopamine is essential for movement. Giving more has not restored movement after stroke.

October 29, 2026 PubMed publication record · Cochrane systematic review of 12 randomized trials; mixed certainty · Primary source

Stroke rehabilitation is one of medicine’s most human enterprises: retraining movement through repetition, attention, feedback and the brain’s capacity to adapt. Dopamine has been proposed as a pharmacologic way to amplify that plasticity. The latest Cochrane review examined whether levodopa or dopamine agonists actually improved motor recovery when rehabilitation was otherwise comparable.

Twelve randomized studies included 1,860 people. Six trials with extractable continuous motor outcomes (1,258 participants) produced a pooled estimate too heterogeneous and imprecise to support benefit (SMD 1.42, 95% CI −0.20 to 3.05; I^2=99%). Crucially, a sensitivity analysis of two trials at low risk of bias representing 1,025 participants found an effect essentially at zero (SMD 0.02, 95% CI −0.10 to 0.14). The pooled serious-adverse-event ratio was 1.03 (95% CI 0.83–1.27). Overall certainty ranged from low to very low.

The finding does not mean dopaminergic signaling is irrelevant to learning; it means these drug strategies have not established better patient movement. Future trials could still test a different subgroup, dose or pairing with rehabilitation, but the intervention has to improve function. This belongs in both The Ascent and the game: training, adaptation and motor control are complex systems, not a single neurotransmitter switch.

Clinical reading: Do not routinely add levodopa solely to enhance poststroke motor recovery on the present evidence.

Source edition: October 30, 2026 · AR-20261030-READER-08 · existing reader feature

09 / The aging brain may be responding to a damaged building block of life

October 30, 2026 PubMed publication record · Preclinical mechanism in aging mice and experimental cells · Primary source

The dementia story has long centered on misfolded proteins, damaged vessels and changes in immune cells. A new experimental paper suggests that an oxidized nucleotide—one of the small molecules cells use constantly—can itself act as an inflammatory signal. The candidate is 8-oxoGTP, an oxidized form of GTP.

Researchers found 8-oxoGTP accumulating in aging mouse brains. Increasing it experimentally activated microglial G-protein signaling and downstream inflammatory pathways, alongside synaptic dysfunction, tau phosphorylation, neuron loss and poorer cognitive performance. Pharmacologic inhibition of Src-family kinases rescued several measured inflammatory and cognitive phenotypes in the experimental setting.

The work is mechanistically intriguing because it connects redox chemistry, cellular signaling and brain immunity. It is not evidence that a supplement, antioxidant, kinase inhibitor or blood test prevents human dementia. The next discriminating experiments concern concentrations in human tissue, the specificity of the signal, other aging pathways and reproducible intervention effects. In our living dementia dossier, this should become a clearly labeled preclinical connection linking nucleotide oxidation to microglial activation—not a prevention claim.

Clinical reading: No present clinical intervention supported; investigate as a mechanistic hypothesis.

Source edition: October 30, 2026 · AR-20261030-READER-09 · existing reader feature

10 / The cells guarding the brain’s blood vessels have their own conversation

October 29, 2026 PubMed publication record · Human tissue / multi-omics association plus experimental animal gene perturbation · Primary source

Brain health depends on more than neurons. Perivascular macrophages sit at the boundary between the brain and its blood supply, where immune signals can affect the vessels that nourish tissue. A Cell paper identifies the transcription regulator cMAF as a driver of a macrophage program that communicates with endothelial cells through IGF1.

In experimental models, deleting cMAF in these macrophages altered their identity and changed transcriptional programs in cerebral arteries. Human datasets supported conservation of the cMAF program. The investigators also observed changes in macrophage cMAF–IGF1 signaling in Alzheimer’s tissue, with a different response in APOE4 carriers. This is an integrated mechanistic picture; the study did not randomize patients to a treatment or report improved dementia outcomes.

What makes the finding worth following is the site of interaction. It suggests that the vascular and immune components of cognitive aging may not be separable into tidy silos. The next useful work is independent cell-specific validation, careful accounting for disease stage and genotype, and interventions that test the causal chain in appropriate models before human studies. Life in the Loop should show the macrophage-to-vessel edge as an experimental mechanism, with the Alzheimer and APOE4 human observations labeled association.

Clinical reading: No new APOE test or therapy indication from this paper alone.

Source edition: October 30, 2026 · AR-20261030-READER-10 · existing reader feature

---

Alive. Awake. Aware.

GO DEEPER

Keep following the question.

The daily issue is a beginning. Choose a reading companion, explore a connection, or return to the wider Arising universe.

Sleep & rhythm →

Strength for the long run →

Browse all public booklets →

Explore the collections →

Follow connections in the Atlas →

Visit Arising Health →

Meet the book →

Meet The Long Game →

The public Atlas connects questions across topics. The book and game pages introduce projects in development.

Alive. Awake. Aware.